®
  • Contact
  • Albumin
  • Products
    • Recombumin®
    • Sample page
  • Albumin Applications
    • COVID-19 Knowledge Hub
    • Cell therapy processing
    • Vaccine stabilization
    • Protein & Peptide formulation
    • Medical device coating
    • Veltis Technology
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

News & Events

World leading manufacturer of recombinant human albumin

Albumedix Media News & Events Jonas S. Møller contributes to PharmaVOICE '2021 Year in Preview'

Jonas S. Møller contributes to PharmaVOICE '2021 Year in Preview'

18 Nov 2020

Acknowledging the "tumultuous year" 2020 has proven to be, PharmaVOICE recently pulled together an interesting review piece, featuring input from several industry experts such as Albumedix CEO; Jonas S. Møller.

Recognizing the positives taken from the year as well as the apparent negatives, the article collates thoughts from a range of contributors, each describing the medical innovations they have been monitoring or contributing to throughout 2020. Thought leaders also shared insights into the trends they'll be keeping an eye on as we move into 2021. 

Regarding Albumedix, Jonas had the following to say:

"This year, the biggest impact on our industry has obviously been the COVID-19 pandemic. As we are supplying customers developing diagnostics, medical devices, and vaccines in the fight against the coronavirus, we are vigilantly watching these developments. Solving challenges in cold-chain storage and transportation are central issues, important in both ensuring COVID-19 vaccines reach patients worldwide, but also an issue advanced therapy developers are addressing to make therapies scalable. Examples here include stability of mRNA vaccines requiring -80°C storage, as well as an increasing trend toward ‘thaw and inject’ of cellular therapies."

Access the full PharmaVOICE article here.

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with ~100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
  • Products
    • Recombumin®
    • Sample page
  • Albumin Applications
    • COVID-19 Knowledge Hub
    • Cell therapy processing
    • Vaccine stabilization
    • Protein & Peptide formulation
    • Medical device coating
    • Veltis Technology
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more